Comparison · NCT02628600-sae
Prior LAI + Multidrug Regimen vs Prior Multidrug Regimen Alone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Prior LAI + Multidrug Regimen vs Prior Multidrug Regimen Alone: serious adverse events. Trial comparisons, record NCT02628600-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02628600-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.274 | 0.185 | 0.386 | wilson | |
| Risk in group 2 | 0.356 | 0.264 | 0.458 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0816 | -0.218 | 0.0625 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.771 | 0.484 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | 0.684 | 0.349 | 1.34 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Prior LAI + Multidrug Regimen than on Prior Multidrug Regimen Alone | 12.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Prior LAI + Multidrug Regimen | Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR. | 20 | 73 | EG000 |
| Group 2 | Prior Multidrug Regimen Alone | Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR. | 32 | 90 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From baseline up to 28 days after end of treatment, up to 13 months
Source ClinicalTrials.gov
Trial
- Title
- Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212
- NCT number
- NCT02628600
- Phases
- PHASE3
- Conditions
- NTM Lung Infection Due to MAC
- Interventions
- LAI 590 mg, Multi-drug regimen
- Lead sponsor
- Insmed Incorporated
- Results first posted
- 2019-11-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02628600?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02628600-sae